AnaptysBio executives will speak at investor conferences on December 2 and 3, 2025, discussing their innovative immunology therapeutics.
Quiver AI Summary
AnaptysBio, Inc., a clinical-stage biotechnology company specializing in immunology therapeutics, announced that its CEO Daniel Faga and other executives will participate in several upcoming investor conferences, including the Piper Sandler 37th Annual Healthcare Conference and the Evercore 8th Annual Healthcare Conference. Live webcasts of their discussions will be accessible on the company's investor website, with replays available for 30 days post-event. AnaptysBio focuses on developing treatments for autoimmune and inflammatory diseases, with a product pipeline that includes rosnilimab for rheumatoid arthritis, ANB033 for celiac disease, and ANB101. Additionally, the company intends to separate its biopharma operations from its royalty assets by the end of 2026 to better align with investor strategies.
Potential Positives
- AnaptysBio is actively engaging with investors by participating in multiple high-profile healthcare conferences, which could enhance visibility and attract potential investments.
- The company is advancing its innovative drug pipeline, including promising candidates like rosnilimab and ANB033, indicating ongoing progress in its therapeutic developments.
- AnaptysBio's strategic decision to separate its biopharma operations from its royalty assets may improve focus and allow investors to better align their investments with specific business objectives.
Potential Negatives
- The announcement of the intent to separate biopharma operations from royalty assets may raise concerns about the company's focus and the potential loss of synergies between these segments.
- The involvement in multiple investor conferences may imply that the company is actively seeking to attract investor interest, potentially indicating current challenges in securing funding or market confidence.
FAQ
What upcoming investor conferences will AnaptysBio participate in?
AnaptysBio will participate in the Piper Sandler 37th Annual Healthcare Conference on Dec. 2, 2025, and Evercore 8th Annual Healthcare Conference on Dec. 3, 2025.
How can I watch the fireside chats?
The fireside chats will be available via live webcasts on the investor section of the AnaptysBio website.
What is AnaptysBio's main focus as a biotechnology company?
AnaptysBio focuses on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases.
What notable assets are in AnaptysBio's pipeline?
AnaptysBio's pipeline includes rosnilimab for rheumatoid arthritis, ANB033 for celiac disease, and ANB101 in a Phase 1a trial.
What is AnaptysBio's recent strategic announcement?
AnaptysBio announced plans to separate its biopharma operations from royalty assets by year-end 2026 to align investment strategies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANAB Insider Trading Activity
$ANAB insiders have traded $ANAB stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ANAB stock by insiders over the last 6 months:
- HOLLINGS RENTON has made 0 purchases and 5 sales selling 34,171 shares for an estimated $766,173.
- ERIC J LOUMEAU (CHIEF LEGAL OFFICER) sold 8,240 shares for an estimated $238,960
- DENNIS M FENTON sold 3,015 shares for an estimated $72,269
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANAB Hedge Fund Activity
We have seen 80 institutional investors add shares of $ANAB stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 2,549,432 shares (-72.0%) from their portfolio in Q3 2025, for an estimated $78,063,607
- MILLENNIUM MANAGEMENT LLC added 1,315,688 shares (+646.4%) to their portfolio in Q3 2025, for an estimated $40,286,366
- BOXER CAPITAL MANAGEMENT, LLC removed 1,300,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,860,000
- UBS GROUP AG removed 1,197,237 shares (-94.1%) from their portfolio in Q3 2025, for an estimated $36,659,396
- CITIGROUP INC removed 975,954 shares (-93.3%) from their portfolio in Q3 2025, for an estimated $29,883,711
- BANK OF AMERICA CORP /DE/ removed 949,558 shares (-88.2%) from their portfolio in Q3 2025, for an estimated $29,075,465
- ASSENAGON ASSET MANAGEMENT S.A. added 822,975 shares (+4852.7%) to their portfolio in Q3 2025, for an estimated $25,199,494
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANAB Analyst Ratings
Wall Street analysts have issued reports on $ANAB in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
- Wedbush issued a "Outperform" rating on 11/24/2025
- Stifel issued a "Buy" rating on 10/29/2025
- Barclays issued a "Overweight" rating on 10/13/2025
- JP Morgan issued a "Overweight" rating on 07/24/2025
To track analyst ratings and price targets for $ANAB, check out Quiver Quantitative's $ANAB forecast page.
$ANAB Price Targets
Multiple analysts have issued price targets for $ANAB recently. We have seen 10 analysts offer price targets for $ANAB in the last 6 months, with a median target of $70.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $51.0 on 11/24/2025
- Martin Fan from Wedbush set a target price of $50.0 on 11/24/2025
- Etzer Darout from Barclays set a target price of $70.0 on 11/11/2025
- John Lee from Truist Securities set a target price of $36.0 on 11/10/2025
- Yatin Suneja from Guggenheim set a target price of $100.0 on 11/05/2025
- Derek Archila from Wells Fargo set a target price of $81.0 on 11/05/2025
- Alex Thompson from Stifel set a target price of $80.0 on 10/29/2025
Full Release
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Piper Sandler 37th Annual Healthcare Conference, New York, NY
- Format – Fireside chat and 1x1 investor meetings
-
Date and Time – Tuesday, Dec. 2, 2025 at 1:30pm ET
Evercore 8th Annual Healthcare Conference, Coral Gables, FL
- Format – Fireside chat and 1x1 investor meetings
- Date and Time – Wednesday, Dec. 3, 2025 at 7:55am ET
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events . Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist ( Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn .
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here .
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
